Pharmaceuticals - Southern Asia

  • Southern Asia
  • In 2024, the projected revenue in the Pharmaceuticals market in Southern Asia is expected to reach US$16.17bn.
  • among the various markets within the market, the largest one is Oncology Drugs which is projected to have a market volume of US$2.44bn in 2024.
  • Looking ahead, the revenue is expected to demonstrate a steady annual growth rate (CAGR 2024-2028) of 5.41%.
  • This growth rate will result in a market volume of US$19.96bn by the year 2028.
  • In terms of global comparison, United States is anticipated to generate the highest revenue, reaching US$636.90bn in 2024.
  • This signifies the significance of the Pharmaceuticals market in Southern Asia.
  • In Southern Asia, India leads the way in pharmaceuticals with its robust domestic market and significant contributions to global drug manufacturing.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Pharmaceuticals market in Southern Asia has been witnessing steady growth in recent years.

Customer preferences:
The customers in Southern Asia have been demanding high-quality, affordable medicines. They are more inclined towards generic medicines due to their cost-effectiveness. Customers also prefer medicines that are easily accessible and available in their local pharmacies.

Trends in the market:
India, being the largest market in Southern Asia, has witnessed a surge in the demand for generic medicines. The Indian government has been promoting the use of generic medicines to make healthcare affordable for all. The pharmaceutical companies are also focusing on research and development to introduce new and innovative medicines. Bangladesh has also been witnessing growth in the pharmaceuticals market due to the increasing demand for essential medicines. The government has been taking steps to ensure the availability of affordable medicines to the masses.

Local special circumstances:
The pharmaceuticals market in Southern Asia is highly regulated. The governments in the region have been taking steps to ensure the availability of affordable medicines to the masses. The governments have also been promoting the use of generic medicines to make healthcare affordable for all. The pharmaceutical companies in the region have been focusing on research and development to introduce new and innovative medicines.

Underlying macroeconomic factors:
The pharmaceuticals market in Southern Asia has been growing due to the increasing population and rising healthcare expenditure. The governments in the region have been investing in healthcare infrastructure to improve healthcare facilities. The increasing prevalence of chronic diseases has also been driving the demand for medicines in the region. The pharmaceuticals market in Southern Asia is expected to witness further growth in the coming years due to the increasing demand for medicines and the government's focus on improving healthcare facilities.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)